38 Results
Sort By:
Published on January 19, 2023
Researchers in Canada have helped explain how the PCSK9 protein degrades low-density lipoprotein (LDL) receptors. Their findings add key insight to the understanding of how atherosclerosis develops. The richest cholesterol particles in the bloodstream, LDLs are strongly linked to cardiovascular disease. But PCSK9 also plays a role in cancer. The…
Published on September 9, 2022
Women and men share most of the same risk factors for cardiovascular disease (CVD), a large international study has found. This was the first such study to include people from low- and middle-income countries where the burden of CVD is the greatest. Women had a lower risk of CVD than…
Published on August 16, 2022
Electronic health records (EHRs) – systems that control all hospital data – have been around since the early 1970s. One of the first, the Health Evaluation thru Logical Processing (HELP) system, was developed by medical informatics pioneer Homer Warner at LDS Hospital, now Intermountain Healthcare, in Salt Lake City, Utah.…
Published on July 12, 2022
Epic Bio, which aims to develop “ultracompact” therapies to modulate gene expression in vivo, today announced its launch and $55 million Series A financing. The biotech was founded by Stanley Qi, Ph.D., a co-inventor on the CRISPR patent held by the University of California. Epic will “revolutionize genetic medicine with…
Published on March 23, 2022
A number of genomic testing companies and laboratories have joined forces to launch the CardioGenomic Testing Alliance (CGTA), a collaborative group with a purpose of raising awareness and the use of genomic assays to test for a variety of cardiovascular conditions. The member companies will work together to advance the…
Published on December 1, 2021
Growing evidence that precision medicine would save lives is what prompted each of the health systems covered in this article to adopt an aggressive program early. “This means improving care for our patients,” says Konstantinos N. Lazaridis, M.D., of Mayo Clinic. “It gives us more specific information about what causes…
Published on March 8, 2021
A polygenic risk score, developed by researchers at Italian health tech company Allelica, can identify people who may be at increased risk for heart disease despite having normal levels of LDL cholesterol. This is important, as currently most assessments for cardiovascular disease risk primarily look at factors such as LDL…
Published on November 20, 2020
In the 1990s, Elissa Levin proposed a master’s thesis on using the Internet to extend the reach of genetic counselors. Quickly, her committee shut down that idea. In those “old days”—just a few decades ago—many genetic counselors believed that only face-to-face assessments could be useful. In the midst of the…
Published on October 5, 2020
Florida’s AdventHealth for Children and Rady Children’s Institute for Genomic Medicine (RCIGM) have announced a partnership that will bring rapid and ultra-rapid whole genome sequencing to help diagnose critically ill infants and children in AdventHealth’s intensive care unit with the aim of providing fast diagnoses of their conditions. The rapid…
Published on March 25, 2020
Robert Green, M.D., MPH, is director of the Boston-based Genomes2People Research Program and new Preventive Genomics Clinic at Brigham and Women’s Hospital, the Broad Institute, and Harvard Medical School. Through his work there on such research initiatives as the REVEAL Study, the MedSeq, and BabySeq Projects, Green has become one…
Published on December 24, 2019
Geisinger Health announced last week that its precision medicine project MyCode reached the milestone enrollment of 250,000 participants in Pennsylvania and New Jersey. To date, the project has both DNA sequence and health data on 145,000 of those participants and has returned medically actionable results to nearly 1,500 participants. “Geisinger…
Published on October 21, 2019
The FH Foundation, a research and advocacy organization focused on familial hypercholesterolemia (FH), published a study today showing that a machine learning model it developed effectively identified individuals with probable FH for the first time at a national scale. The FH Foundation study was designed to validate and implement the…
Published on October 7, 2019
Since the completion of the Human Genome Project in 2003, the pharmacogenomics industry has experienced waxes and wanes in reaction to healthcare dynamics and technological advancements.[i] With the continued push towards personalized medicine, pharmacogenetics offers organizations a potential solution to fine-tune therapy by helping predict the patient’s response to a…
Published on July 24, 2019
Personal genomics company Helix is partnering with the Central Florida Division of healthcare provider AdventHealth in an ambitious study that will screen participants for four genes linked to familial hypercholesterolemia (FH). The study, titled WholeMe, will give 10,000 participants the opportunity to have Helix screen for pathogenic variants in the…
Published on April 26, 2019
Regional, non-profit healthcare delivery network AdventHealth (formerly Adventist Health System) announced it will partner with personal genomics company Helix to screen up to 10,000 patients for familial hypercholesterolemia (FH), an inherited condition that can lead to high cholesterol levels and potentially serious health problems. The AdventHealth program, called WholeMe, is…